Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Eikon Therapeutics, OpenAI, and 370+ companies. 5-min read every Tuesday.
Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.
| Industry | Biotechnology |
| Stage | Series A |
| IPO Status | Private |
| Valuation | $500M |
| Total Funding | $771M |
| Headquarters | Hayward, CA |
OpenAI is valued at $852B — the world's most valuable AI company, backed by $27B in funding. Track IPO readiness score, funding rounds, and timeline.
| Industry | Artificial Intelligence |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $852B |
| Total Funding | $55.4B |
| Headquarters | San Francisco, CA |
Eikon Therapeutics is valued at $500M. OpenAI is valued at $852B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Eikon Therapeutics has raised $771M. OpenAI has raised $55.4B.
Eikon Therapeutics is currently private. OpenAI is currently pre-IPO. Track both on TechStackIPO for S-1 filings and IPO announcements.
Eikon Therapeutics operates in Biotechnology, while OpenAI operates in Artificial Intelligence.
Eikon Therapeutics is a Biotechnology company valued at $500M with $771M raised. OpenAI is a Artificial Intelligence company valued at $852B with $55.4B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Eikon Therapeutics and OpenAI through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.